prikaz prve stranice dokumenta Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability
  Download
PDF 10.51 MB
Scientific paper - Original scientific paper
Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability
Journal of Physiology and Pharmacology, 64 (2013), 5; 597-612. urn:nbn:hr:105:280120
Kliček, Robert; Kolenc, Danijela; Šuran, Jelena; Drmić, Domagoj; Brčić, Luka; Aralica, Gorana; Sever, Marko; Holjevac, J.; Radić, Božo; Turudić, Tanja; Kokot, A.; Patrlj, Leonardo; Rucman, Rudolf; Seiwerth, Sven; Sikirić, Predrag More authors...

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Kliček, R., Kolenc, D., Šuran, J., Drmić, D., Brčić, L., Aralica, G. ... Sikirić, P. (2013). Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. Journal of Physiology and Pharmacology, 64. (5), 597-612. Retrieved from https://urn.nsk.hr/urn:nbn:hr:105:280120

Kliček, Robert, et al. "Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability." Journal of Physiology and Pharmacology, vol. 64, no. 5, 2013, pp. 597-612. https://urn.nsk.hr/urn:nbn:hr:105:280120

Kliček, Robert, Danijela Kolenc, Jelena Šuran, Domagoj Drmić, Luka Brčić, Gorana Aralica, Marko Sever, et al. "Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability." Journal of Physiology and Pharmacology 64, no. 5 (2013): 597-612. https://urn.nsk.hr/urn:nbn:hr:105:280120

Kliček, R., et al. (2013) 'Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability', Journal of Physiology and Pharmacology, 64(5), pp. 597-612. Available at: https://urn.nsk.hr/urn:nbn:hr:105:280120 (Accessed 28 April 2024)

Kliček R, Kolenc D, Šuran J, Drmić D, Brčić L, Aralica G, and sur.. Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. Journal of Physiology and Pharmacology [Internet]. 2013 October [cited 2024 April 28];64(5):597-612. Available at: https://urn.nsk.hr/urn:nbn:hr:105:280120

R. Kliček, et al., "Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability", Journal of Physiology and Pharmacology, vol. 64, no. 5, pp. 597-612, October 2013. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:280120. [Accessed: 28 April 2024]

Metadata
Title (english)Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability
AuthorRobert Kliček
AuthorDanijela Kolenc
AuthorJelena Šuran
AuthorDomagoj Drmić
AuthorLuka Brčić
AuthorGorana Aralica
AuthorMarko Sever
AuthorJ. Holjevac
AuthorBožo Radić
AuthorTanja Turudić
AuthorA. Kokot
AuthorLeonardo Patrlj
AuthorRudolf Rucman
AuthorSven Seiwerth
AuthorPredrag Sikirić
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Abstract (english)
Stable gastric pentadecapeptide BPC 157 was suggested to link inflammatory bowel disease and multiple sclerosis, and thereby, shown to equally counteract the models of both of those diseases. For colitis, cysteamine (400 mg/kg intrarectally (1 ml/rat)) and colon-colon anastomosis (sacrifice at day 3, 5, 7, and 14) were used. BPC 157 (10 μg/kg, 10 ng/kg) was applied either intraperitoneally once time daily (first application immediately after surgery, last at 24 hours before sacrifice) or per-orally in drinking water (0.16 μg/ml/12 ml/day till the sacrifice) while controls simultaneously received an equivolume of saline (5 ml/kg) intraperitoneally or drinking water only (12 ml/day). A multiple sclerosis suited toxic rat model, cuprizone (compared with standard, a several times higher regimen, 2.5% of diet regimen + 1 g/kg intragastrically/day) was combined with BPC 157 (in drinking water 0.16 μg or 0.16 ng/ml/12 ml/day/rat + 10 μg or 10 ng/kg intragastrically/day) till the sacrifice at day 4. In general, the controls could not heal cysteamine colitis and colon-colon anastomosis. BPC 157 induced an efficient healing of both at the same time. Likewise, cuprizone-controls clearly exhibited an exaggerated and accelerated damaging process; nerve damage appeared in various brain areas, with most prominent damage in corpus callosum, laterodorsal thalamus, nucleus reunions, anterior horn motor neurons. BPC 157-cuprizone rats had consistently less nerve damage in all damaged areas, especially in those areas that otherwise were most affected. Consistently, BPC 157 counteracted cerebellar ataxia and impaired forelimb function. Thereby, this experimental evidence advocates BPC 157 in both inflammatory bowel disease and multiple sclerosis therapy.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleJournal of Physiology and Pharmacology
Numberingvol. 64, no. 5, pp. 597-612
p-ISSN0867-5910
URN:NBNurn:nbn:hr:105:280120
Publication2013-10
Document URLhttp://www.jpp.krakow.pl/journal/archive/10_13/pdf/597_10_13_article.pdf
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-27 20:01:29